Treatment
Olaparib clinical trials
We’re tracking 83 recruiting studies that include Olaparib, each written for real people, not researchers, below.
Recruiting studies
- NCT06380738Recruiting
Real-world study of olaparib plus abiraterone for advanced prostate cancer
This trial is for people with advanced prostate cancer (mCRPC) who are already taking the combination of olaparib and abiraterone. It will look at how these two medicines work together in real-world practice.
AschaffenburgAges 18 years+ - NCT06298084RecruitingPhase 1/Phase 2
HER3-DXd for Advanced Breast Cancer After T-DXd
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
VillejuifAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Birmingham, AlabamaAges Any age - NCT07652242RecruitingPhase 1
A RNA vaccine for stage 2-3 triple negative breast cancer
This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.
Grand Rapids, MichiganAges 18 years+ - NCT02029001RecruitingPhase 2
Personalized treatment matched to your tumor’s DNA changes
This Phase 2 study tests whether choosing cancer drugs based on specific DNA or blood test results from your tumor can work better for people with advanced solid tumors. It aims to use a molecular tumor board’s recommendation to guide the safest, most likely targeted treatment for each patient.
BordeauxAges 18 years+ - NCT06856499RecruitingPhase 1
Cirtuvivint and Olaparib for BRCA-related ovarian cancer
This trial tests a combination of two targeted drugs, cirtuvivint and olaparib, for a specific type of ovarian cancer that no longer responds to platinum chemotherapy. It may be an option if you have a BRCA mutation or HRD-positive tumor and have already tried a PARP inhibitor.
Aurora, ColoradoAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Goodyear, ArizonaAges 18 years+ - NCT03150576RecruitingPhase 2/Phase 3
Before-surgery treatment for triple-negative or BRCA breast cancer
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Cambridge, CambridgeshireAges 16–70 - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+ - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+ - NCT04005690RecruitingEarly Phase 1
Targeted drug treatment for pancreatic cancer using pathway changes
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Portland, OregonAges 18 years+ - NCT04550104RecruitingPhase 1
Durvalumab with radiation for lung cancer patients
This trial tests adding durvalumab (an immune therapy) to a radiation treatment plan for people with non-small cell lung cancer (NSCLC) who can’t safely have chemotherapy at the same time or surgery first. It aims to improve cancer control after radiation by helping the immune system recognize and fight the tumor.
BelfastAges 18 years+ - NCT05255653RecruitingPhase 2/Phase 3
Personalized after-surgery treatment for endometrial cancer by tumor type
This trial studies which after-surgery (adjuvant) treatment works best when endometrial cancer is classified by specific tumor DNA/molecular features. You may be offered treatment based on the tumor results, aiming to improve outcomes and lower the risk of the cancer coming back.
TorontoAges 18 years+ - NCT05332561RecruitingPhase 2
Personalized treatment after surgery for early breast cancer
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05432518RecruitingEarly Phase 1
Pilot study for surgery and new medicine in recurrent glioblastoma
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
Calgary, AlbertaAges 18 years+ - NCT05485766RecruitingPhase 2
Pembrolizumab with cancer medicines for BRCA-mutated triple negative breast cancer
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
Gifu, GifuAges 18 years+ - NCT05870423RecruitingPhase 1
Testing PARP inhibitors with peptide radiation for NET
This early-phase study tests whether adding a medicine called a PARP inhibitor to peptide receptor radionuclide therapy (PRRT) can better control advanced or metastatic neuroendocrine tumors (NET). It may help by targeting tumor DNA repair while PRRT delivers targeted radiation.
Rotterdam, South HollandAges 18 years+ - NCT05898399RecruitingPhase 1/Phase 2
Testing ART6043 for advanced cancers with DNA repair defects
This early-phase study tests ART6043 in people with advanced or metastatic solid tumors, and in some parts with breast cancer plus specific gene changes. The goal is to see how well it works and whether it is safe, sometimes combined with olaparib.
Grand Rapids, MichiganAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Fountain Valley, CaliforniaAges 18 years+ - NCT06245889RecruitingPhase 2
PET-Guided Therapy for Triple-Negative Breast Cancer
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT02813135RecruitingPhase 1/Phase 2
Targeted cancer treatment chosen by a tumor’s genetic findings
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
CopenhagenAges Up to 18 years - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06437353RecruitingPhase 2
Surufatinib combo for first-line and maintenance in high-risk ovarian cancer
This trial tests a combination of drugs (Surufatinib with carboplatin/paclitaxel) as first treatment for high-risk ovarian cancer, followed by a different combination (Surufatinib with olaparib) to keep the cancer from coming back. It aims to see if these targeted therapies work better than the standard approach.
Hefei, AnhuiAges 18–75 - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Orlando, FloridaAges 18 years+
Common questions
- Are there clinical trials studying Olaparib?
- Yes. Clin2 currently lists 83 recruiting studies that include Olaparib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Olaparib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Olaparib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Olaparib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.